AXL recombinant proteins and antibodies

AXL, also known as Ark, Ufo and Tyro-7, is a receptor tyrosine kinase. It was first discovered by Liu E et al. in 1988 when screening genes related to chronic to acute transformation of myeloid leukemia (CML). Under normal physiological conditions, the expression of AXL is mostly confined to smooth muscle, lung, kidney, testis and blood in normal cells. In studies of many cancer cells, it was found that AXL is highly expressed in a variety of cancers such as non-small cell lung cancer, breast cancer, and ovarian cancer, and is closely related to the occurrence, development, and drug resistance of tumors.

Like other TAM family receptors, AXL generally integrates extracellular signals through classical ligand binding to induce effective intracellular signal transduction in order to respond to various biological processes, such as inflammatory responses. There are two ways of AXL activation, one is classical ligand-dependent activation (mainly), and the other is non-Gas6-dependent activation. The classical ligand-dependent activation of AXL refers to the AXL/Gas6 signaling pathway. Gas6-independent activation of the AXL receptor refers to the activation of AXL by interacting with two other TAM receptors (Mer and Tyro-3) and several other non-TAM family member proteins (such as EGFR, HER2, etc.). More about the mechanism of action and signaling pathway of AXL >>

According to the data from the Clinical trail, the current clinical drugs targeting AXL are still mainly small molecule compounds, and there are only 5 drugs based on immunotherapy, including 3 ADCs, 1 CAR-T, and 1 antibody.

In order to accelerate the development of AXL target drugs, DIMA BIOTECH can provide a full range of AXL target products and services, covering a variety of active proteins, flow-validated monoclonal antibodies and reference antibodies. Services include humanization, affinity maturation, and removal of PTM risk sites. In addition, Dima has also prepared a B cell seed library for AXL, and the lead antibody molecule screening can be completed in as fast as 20 days.